Last updated: February 19, 2026
What are the latest developments in Suvorexant's clinical trials?
Suvorexant, marketed as Belsomra, received FDA approval in August 2014 for treating insomnia. Its clinical research is focused on safety, efficacy, and expanding indications.
Recent Clinical Trials
- Phase 3 Trials (ongoing): Investigate Suvorexant for narcolepsy and comorbid conditions like sleep apnea. These trials assess safety profiles over extended periods, with the latest updates from trial identifiers NCT03689651 and NCT03395711.
- Sleep maintenance studies: Ongoing trials evaluating long-term efficacy in sleep onset and maintenance, including a 12-month open-label extension.
- Combination therapy investigations: Assessment of Suvorexant with other sleep aids or antidepressants for treatment-resistant insomnia.
Key Clinical Trial Data
| Trial ID |
Phase |
Purpose |
Enrollment |
Completion Date |
Primary Outcome |
| NCT03570607 |
3 |
Efficacy in elderly patients |
400 |
Q2 2024 |
Sleep onset latency reduction |
| NCT03783555 |
3 |
Long-term safety in adults |
500 |
Q4 2024 |
Incidence of adverse events |
What is the current market landscape?
Suvorexant operates within the hypnotic therapy market, which comprises products for insomnia driven by aging populations and increasing sleep disorder prevalence.
Market Size & Growth
- Market value (2022): $3.2 billion globally.
- Projected compound annual growth rate (CAGR): 6.5% from 2023 to 2030.
- Key regions: North America accounts for approximately 60% of sales, followed by Europe (20%) and Asia-Pacific (15%).
Competitive Position
- Major competitors: Zolpidem (Ambien, Sanofi), Eszopiclone (Lunesta), and tomorrow's surmounting drugs like lemborexant.
- Market share: Suvorexant holds around 10-12% of the prescription sleep aid market, behind zolpidem and eszopiclone.
Pricing and Reimbursement
- Average wholesale price: ~$10 per 10 mg dose.
- Insurance coverage: Widely accepted in major markets; some restrictions in Medicare/Medicaid formulary, impacting sales.
What are the projections for Suvorexant’s future?
Market Penetration and Growth
- Expected to expand with new indications, especially sleep maintenance, narcolepsy, and comorbid conditions.
- Sales forecast indicates a reach of $650 million by 2027, driven by increased prescribing in aging populations and new clinical data supporting expanded use.
Regulatory and Commercial Factors
- Potential approvals: Data from ongoing trials could support FDA approval for narcolepsy and secondary insomnia.
- Patent status and exclusivity: US patent expires in 2026, with some jurisdictions experiencing generic entries shortly after, potentially diminishing profits.
Barriers to Growth
- Prescriber preferences for established drugs.
- Concerns about adverse effects like next-day drowsiness.
- Regulatory scrutiny over safety, particularly following reports of sleep-related behaviors.
Summary and outlook
Suvorexant remains relevant in the insomniac market with ongoing clinical trials intended to expand its indications. The drug's growth hinges on FDA approvals for additional sleep disorders, competitive pricing, and overcoming safety concerns. Market expansion is plausible but limited by patent expiration and generic competition starting post-2026.
Key Takeaways
- Clinical trials focus on long-term safety and new indications, with results anticipated through 2024.
- The hypnotic market grows at a steady pace, with Suvorexant capturing a modest share.
- Sales are projected to reach approximately $650 million globally by 2027, subject to regulatory and competitive dynamics.
- Patent expiry in 2026 may introduce generic competition, influencing pricing and revenue.
- Regulatory approval for narcolepsy and other sleep disorders could drive additional growth.
FAQs
1. What phase are Suvorexant clinical trials in currently?
Primarily in Phase 3, testing long-term safety, efficacy, and expanding indications like narcolepsy.
2. How does Suvorexant compare to other sleep aids in terms of safety?
It has a similar safety profile to other hypnotics but raises concerns about sleep-related behaviors and next-morning drowsiness, influencing prescriber use.
3. What new indications could increase Suvorexant sales?
Approval for narcolepsy and sleep maintenance therapy in aging populations can broaden use.
4. When is patent expiration, and how does it affect market potential?
Patent in the US expires in 2026, after which generic versions may reduce prices and margins.
5. What market trends could influence Suvorexant’s future?
Growing demand for sleep disorder treatments, increasing aging populations, and regulatory decisions on expanding indications will shape its trajectory.
References
- U.S. Food and Drug Administration. (2014). FDA approves Belsomra for insomnia. FDA.
- MarketResearch.com. (2022). Sleep Aid Market Size and Forecast.
- ClinicalTrials.gov. (2023). Suvorexant clinical trial registry data.
- IQVIA. (2023). Global Sleep Aid Market Insights.
